Trial
NCT00925132
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Iowa
Collaborators
Holden Comprehensive Cancer Center; Novartis Pharmaceuticals
Condition
Metastatic Melanoma
Intervention
Temozolomide, Decitabine, Panobinostat
Why stopped
Change in the number of approved drugs for metastatic melanoma
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-07-02